Cambridge, United Kingdom

Ioana Sovago

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Cardurion Pharmaceuticals, LLC. Active years: 2024-2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ioana Sovago: Innovator in Pharmaceutical Chemistry

Introduction

Ioana Sovago is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds. With a total of 2 patents to her name, her work is recognized for its innovative approach to drug formulation.

Latest Patents

Ioana's latest patents focus on the monohydrate and crystalline forms of a specific compound, 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one. The present disclosures relate to the crystalline polymorph forms of this compound, which are crucial for enhancing the efficacy and stability of pharmaceutical products.

Career Highlights

Ioana is currently employed at Cardurion Pharmaceuticals, LLC, where she continues to push the boundaries of pharmaceutical research. Her work has been instrumental in advancing the understanding of drug properties and their applications in medicine.

Collaborations

Throughout her career, Ioana has collaborated with notable colleagues, including Mateusz Pitak and Adam Ross Patterson. These partnerships have fostered a dynamic research environment that encourages innovation and discovery.

Conclusion

Ioana Sovago's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in the field. Her patents and collaborations highlight her commitment to advancing medical science through research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…